스마트 약물전달 시스템 시장 기회, 성장 촉진요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Smart Drug Delivery Systems Market was valued at USD 13.9 billion in 2025 and is estimated to grow at a CAGR of 16.7% to reach USD 64.5 billion by 2035.

Market growth is supported by the increasing burden of chronic diseases, rising adoption of digital healthcare solutions, and a growing shift toward patient-focused and home-based treatment approaches. The rising incidence of long-term health conditions is driving demand for more precise and efficient therapeutic solutions, as conventional drug delivery methods often lack accuracy and consistency. Smart drug delivery technologies address these challenges by enabling controlled, targeted, and programmable drug administration, significantly improving treatment effectiveness and patient compliance. In parallel, healthcare systems are increasingly emphasizing convenience, cost optimization, and improved patient outcomes, encouraging the use of advanced delivery systems outside traditional clinical environments. Continuous technological advancements, combined with the integration of connected devices and data-driven healthcare models, are further accelerating the adoption of these systems, positioning them as a critical component in the evolution of modern healthcare delivery.

The connected inhalers segment generated USD 5 billion in 2025, holding a substantial share within the smart drug delivery systems market. These devices are gaining widespread adoption due to their ability to address persistent challenges in respiratory care, including inconsistent medication usage and limited visibility into patient adherence. By incorporating digital tracking capabilities, connected inhalers enable accurate monitoring of usage patterns and dosing frequency, improving overall treatment management. The increasing adoption of remote healthcare services and digitally integrated treatment solutions is further supporting the growth of this segment.

The neurological disorders segment accounted for USD 5.5 billion in 2025. This segment is driven by the need for precise and consistent drug administration to manage complex conditions affecting the nervous system. Such conditions often require continuous and controlled medication delivery to maintain stability and prevent complications. Smart drug delivery systems provide advanced capabilities such as automated dosing and real-time monitoring, helping to overcome challenges associated with traditional treatment methods and improving patient outcomes.

North America Smart Drug Delivery Systems Market accounted for 45.7% share in 2025. The region is witnessing strong growth due to the increasing prevalence of chronic conditions and the rapid adoption of digital health technologies. A well-developed healthcare infrastructure, combined with widespread implementation of connected medical devices, is supporting the integration of advanced drug delivery solutions. The growing use of remote monitoring, data-driven healthcare systems, and automated treatment approaches is further enhancing market expansion. Continuous innovation in digital health tools and connected care solutions is creating a favorable environment for the adoption of smart drug delivery technologies.

Key companies operating in the Global Smart Drug Delivery Systems Market include Amiko Digital Health, Becton Dickinson and Company, Biocorp, Elcam Medical, Medtronic, Medtrum, Nemera, Novo Nordisk, Phillips-Medisize, Portal Instruments, Teva Pharmaceutical Industries, West Pharmaceutical Services, Ypsomed, Haselmeier, and Insulet. Companies in the Smart Drug Delivery Systems Market are strengthening their market position through continuous innovation, strategic partnerships, and expansion of digital capabilities. A primary focus is being placed on integrating advanced technologies such as connected devices and data analytics to enhance treatment precision and patient engagement. Firms are investing heavily in research and development to introduce next-generation delivery systems with improved accuracy and usability. Collaborations with healthcare providers and technology companies are helping expand product reach and adoption. Additionally, companies are focusing on developing patient-centric solutions that support home-based care. Geographic expansion, along with the enhancement of product portfolios and digital ecosystems, remains a key strategy to capture emerging opportunities and sustain long-term growth.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Product trends
  • 2.2.2 Application trends
  • 2.2.3 Route of Administration trends
  • 2.2.4 End Use trends
  • 2.2.5 Regional trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of chronic diseases
    • 3.2.1.2 Growing adoption of digital health technologies
    • 3.2.1.3 Shift towards patient-centric and home-based care
    • 3.2.1.4 Technological advancements in drug delivery
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost associated with device development and production
    • 3.2.2.2 Lack of standardization
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion of connected and data-driven drug delivery platforms
• 3.3 Growth potential analysis (Driven by Primary Research)
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
• 3.5 Technology landscape (Driven by Primary Research)
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Future market trends (Driven by Primary Research)
• 3.7 Impact of AI and generative AI on the market
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard
• 4.7 Key developments
  • 4.7.1 Mergers and acquisitions
  • 4.7.2 Partnerships and collaborations
  • 4.7.3 New product launches
  • 4.7.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Connected inhalers
• 5.3 Connected autoinjectors
• 5.4 Connected pen injectors
• 5.5 Connected wearable injectors
• 5.6 Add-on sensors
• 5.7 Other products

Chapter 6 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Metabolic disorders
• 6.3 Neurological disorders
• 6.4 Respiratory disorders
• 6.5 Hormonal disorders
• 6.6 Other applications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Injectable
• 7.3 Inhalation
• 7.4 Oral

Chapter 8 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Clinics
• 8.4 Home care
• 8.5 Ambulatory care settings
• 8.6 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Amiko Digital Health
• 10.2 Becton, Dickinson and Company
• 10.3 Biocorp
• 10.4 Elcam Medical
• 10.5 Medtronic
• 10.6 Medtrum
• 10.7 Nemera
• 10.8 Novo Nordisk
• 10.9 Phillips-Medisize
• 10.10 Portal Instruments
• 10.11 Teva Pharmaceutical Industries
• 10.12 West Pharmaceutical Services
• 10.13 Ypsomed
• 10.14 Haselmeier
• 10.15 Insulet